NCT03596281View on ClinicalTrials.gov

Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

March 11, 2021

Study Completion Date

April 11, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Pembrolizumab

200mg Q3W IV

DRUG

Bevacizumab

400 or 300 mg Q3W IV

DRUG

pegylated liposomal doxorubicin (PLD)

15 or 20 or 30 mg/m² Q3W IV

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT03596281 - Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer | Biotech Hunter | Biotech Hunter